Fourteen patients with high-risk T-lineage acute lymphoblastic leukemia (ALL) in complete remission underwent autologous bone marrow transplantation (BMT) in an attempt t o eradicate their residual disease burden. A combined immunochemotherapy protocol using a cocktail of t w o immunotoxins directed against CD5/Tp67 and CD7/Tp41 T-lineage differentiation antigens in combination with the in vitro active cyclophosphamide congener 4hydroperoxy-cyclophosphamide (4-HC) was used t o purge autografts. Despite high dose pretransplant radiochemotherapy and effective purging of autografts. 9 of 14 patients relapsed at a median of 2.5 months (range. 1.2 t o 16.8 months) post BMT. Two patients remain alive and disease free at 26 and 28 months post BMT. We used a novel quantitative minimal residual disease (MRD) detection assay, which combines fluorescence activated multiparameter flow cytometry and cell sorting with leukemic progenitor cell (LPC) assays, t o analyze remission bone marrow (BM) samples from T-lineage ALL patients for the presence of residual LPCs.
Fourteen patients with high-risk T-lineage acute lymphoblastic leukemia (ALL) in complete remission underwent autologous bone marrow transplantation (BMT) in an attempt t o eradicate their residual disease burden. A combined immunochemotherapy protocol using a cocktail of t w o immunotoxins directed against CD5/Tp67 and CD7/Tp41 T-lineage differentiation antigens in combination with the in vitro active cyclophosphamide congener 4hydroperoxy-cyclophosphamide (4-HC) was used t o purge autografts. Despite high dose pretransplant radiochemotherapy and effective purging of autografts. 9 of 14 patients relapsed at a median of 2.5 months (range. 1.2 t o 16.8 months) post BMT. Two patients remain alive and disease free at 26 and 28 months post BMT. We used a novel quantitative minimal residual disease (MRD) detection assay, which combines fluorescence activated multiparameter flow cytometry and cell sorting with leukemic progenitor cell (LPC) assays, t o analyze remission bone marrow (BM) samples from T-lineage ALL patients for the presence of residual LPCs.
ODERN MULTI-AGENT intensive chemotherapy
M results in long-term disease-free survival (DFS) in 50% to 80% of patients with acute lymphoblastic leukemia (ALL), and a substantial proportion of these patients are cured of their di~ease.'.~ However, some ALL patients are at high risk for relapse following the currently available firstline chemotherapeutic regimens. Although a prolonged second remission can be attained by intensive salvage chemotherapy in patients who relapse while off treatment, patients who experience a medullary relapse during or shortly after their first-line chemotherapy have a poor outcome.' A number of centers have investigated the role of high-dose radiochemotherapy followed by allogeneic or autologous bone marrow transplantation (BMT) for the treatment of high-risk remission ALL.4-" Recent reports indicate that BMT may be more effective than chemotherapy in a number of high risk ALL patients, especially those who relapse within 18 months after first-line chemotherapy.ls6 More than two thirds of otherwise eligible BMT candidates with high risk remission ALL do not have a matched sibling donor for allogeneic BMT. For these patients autologous BMT has emerged as a potentially curative alternative therapy.'."
This report details our preclinical and clinical data in 14 consecutive patients with high-risk remission T-lineage ALL who were prepared for BMT with either high dose cytarabine (ARA-C) in combination with total body irradiation (TBI) or hyperfractionated TBI followed by cyclophosphamide, and who received autografts that were purged ex vivo using the anti-CD5 (Tp67) immunotoxin T101-Ricin plus the anti-CD7 (Tp41) immunotoxin G3.7-Ricin combined with 4-hydroperoxycyclophosphamide (4-HC). Remission bone marrow (BM) samples were analyzed for the presence of residual T-lineage leukemic progenitor cells (LPCs) using a quantitative minimal residual disease (MRD) detection assay system, which combines fluorescence activated multipaNotably, high numbers of residual LPC detected in remission BM before BMT constituted a poor prognostic indicator, providing the first evidence for the biologic significance and clinical value of in vitro T-lineage ALL LPC assays. The median value for the residual leukemia burden before BMT.
was -8.6 x lo3 LPC/108 mononuclear cells (MNC) (-0.0086% LPC). Patients with a residual leukemia burden less than this median value appeared t o have a better outlook for remaining free of relapse after autologous BMT than patients with a greater leukemia burden (53 k 25% Y 14 13%. P = .006, Mantel-Cox). By comparison, the log kill efficacy of purging, the remaining numbers of LPC in purged autografts, or the estimated numbers of reinfused LPC, did not correlate with the probability of disease-free survival (DFS). These results indicate that the primary reason for the recurrence of leukemia was inefficient pretransplant radiochemotherapy rather than inefficient purging of autografts. 0 1990 by The American Society of Hematology.
rameter flow cytometry and sterile cell sorting with LPC assays. Our findings provide initial evidence for the clinical value of this M R D detection assay, which appears to predict the outcome of autologous BMT.
UCKUN ET AL
enrolled in a clinical study of autologous BMT for high-risk T-lineage ALL. Follow-up was complete through May 1990. The study protocol was approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota, and written informed consent was obtained from all patients before entering the study according to Department of Health and Human Services (DHHS) guidelines. To be eligible for this protocol, patients had to have leukemic blasts that were immunophenotyped at diagnosis or relapse and found positive for CD5(T,p67) and/or CD7(T,p41) T-lineage differentiation antigens. Eligible patients included: (1) all patients less than 45 years of age and in second or third BM remission who lacked a histocompatible matched donor; (2) highrisk adolescents, defined as patients 16 to 20 years of age whose (a) WBC at the time of diagnosis was greater than lO,OOO/pL, or (b) leukemic blasts displayed structural chromosomal abnormalities (eg, translocations, deletions) in their first or subsequent remission; (3) children less than 16 years of age whose leukemic blasts had either a 4;ll translocation or a Philadelphia chromosome in their first or subsequent remission; and (4) adults 21 to 45 years of age in their first or subsequent remission. Patients who had a chemotherapyinduced remission after experiencing an isolated extramedullary relapse while receiving maintenance chemotherapy were eligible. Patients relapsing more than 1 year after cessation of maintenance chemotherapy were not eligible.
Immunologic marker analyses of ALL BM mononuclear cell suspensions by indirect immunofluorescence and flow cytometry were performed as previously described in detai1.l2.l6 Samples were scored positive when more than 20% of cells bound the antibody used.
BM was harvested under general anesthesia by multiple aspirations from the iliac crests in volumes to yield a minimum of 4.5 x 10' nucleated cells/kg. The BM was processed and treated ex vivo with a combination of two immunotoxins and 4-HC, as described below; 0.5 to 1.0 x 10' nucleated cells were stored untreated as backup BM to be used in case of graft failure.
Anti-CDS monoclonal antibody (MoAb) TI01 (IgG2a) and antLCD7 MoAb (33.7 ( I g G l ) were linked to intact ricin, as previously BM MNC were transferred to 5-L Bellco bottles with a stir bar containing a prewarmed solution of RPMI 1640 supplemented with 300 mmol/L lactose plus 2% human serum albumin (HSA) plus 2% penicillin streptomycin (PS) plus an appropriate amount of the immunotoxin cocktail to yield a final cell concentration of 10 x lo6 cells/mL, a final immunotoxin concentration of 500 ng/mL for TI01 (anti-CDS) Ricin and 500 ng/mL for (33.7 (anti-CD7) Ricin, and a final lactose concentration of 200 mmol/L. Cells were incubated at 37OC and 5% CO, under stirring at a moderate speed. After 90 minutes of incubation, an appropriate amount of a freshly prepared buffered 4-HC stock solution was added to each bottle to yield a final concentration of 10 pg/mL and a pH of 7.4 without significantly changing the final cell or immunotoxin concentrations. Following another 30 minutes of incubation at 37°C and 5% CO,, the reaction was stopped with cold medium and cells were washed in cold medium twice to remove remaining 4-HC and unbound immunotoxin. After this purging procedure, cells were resuspended at a concentration of 50 to 100 x lo6 nucleated cells/mL, and autologous irradiated or microporefiltered plasma and cold dimethylsulfoxide as cryoprotectant (Cryoserv; Research Industries Corp, Salt Lake City, UT) were rapidly added to give a final volume proportion of 10% for each in freezing bags (Delmed, Canton, MA). Bags were immediately transferred to a controlledrate freezer equipped with a model 1010 microcomputer programmable freezing controller for precision cooling rates (Cryomed Freezing System; Cryomed, Mt Clemens, MI), brought to 0°C and cooled to lmmunologic surface marker anaIyses.
Bone marrow harvest.
Ex vivo purging of autologous bone marrow grafts.
described. I2.14.17.18 -6OOC at -I0C/min, and then to -1OOOC at -3"C/min. Frozen bags were stored in liquid nitrogen until reinfusion.
Detection of residual leukemic blasts in autologous marrow grafts before and after purging. Ficoll-Hypaque separated BM MNCs from prepurge and postpurge samples of autologous BM grafts were analyzed by two-color immunofluorescence for the "early" T-lineage cell surface differentiation antigens CD5 and CD7 using a mixture of FITC labeled 10.2 (anti-CDS) and G3.7 (anti-CD7) MoAbs and the "late" T-lineage cell surface differentiation antigen CD3 using the phycoerythrin (PE) conjugate of (319.4 (anti-CD3) MoAb, as described Sterile cell sorting at 1,500 cells/s was performed to isolate viable CD5,7(green)+ CD3(red)-T-cell precursors as well as CD5,7+CD3+ T-lineage cells, as described p r e v i~u s l y . '~~~~ CD5,7+CD3+ cell fractions were analyzed since some ALL cases had a CD3' mature T-cell ALL immunophenotype. FACS sorted cells were assayed for T-lineage ALL blast colony formation in a LPC assay system, as reported in detail in previous publication^.'^^" After 7 days of culture, whole petri dishes containing the cultures were harvested for morphologic and immunologic characterization of colony cells.
Preparative regimens and supportive care. Two different pretransplant preparative regimens were used in this study. The first nine consecutive patients were prepared with single dose TBI (850 cGy total dose delivered using 10-MeV x-rays at a dose rate of 26 cGy/min on day -8) followed by 12 doses of Ara-C on days -7 through -2 at a dose of 3 g/m2 administered as a I-hour intravenous (IV) infusion twice daily (total dose of Ara-C, 36 g/m2) (regimen A). In an attempt to decrease the posttransplant relapse rate, the last five consecutive patients were prepared with hyperfractionated TBI (1,375 cGy total dose delivered in 11 x 125 cGy fractions on days -7, -6, -5, and -4) followed by 60 mg/kg/d cyclophosphamide on days -3 and -2, which was administered as a 1-hour IV infusion on each day (regimen B). After 1 day of rest (day -I), autologous BM grafts were thawed and administered on day 0. The details of these preparative regimens were published p r e v i~u s l y .~~~~~~~ Supportive care during the hospital stay was provided as previously detailed.'.l9
The clinical and laboratory data were retrieved from the University of Minnesota BMT Data Base, which systematically and prospectively collects data on all of our BM transplant recipients. The data were analyzed by standard statistical methods with the assistance of the BMDP-87 software program. Posttransplant event times were measured from the day of BMT to the day of relapse, death, or last follow-up. DFS was defined as the time from date of BMT to date of relapse or death, whichever occurred first. The probabilities for DFS and for remaining in remission were estimated and relapse free interval curves were generated using the Kaplan-Meier product limit method.
Data analysis.

RESULTS
Pretransplant characteristics of patients. Fourteen consecutive patients were enrolled in this study. T h e pretransplant characteristics of patients a r e detailed in Table 1 .
There were 2 females and 1 2 males with a median age of 14 years (range, 6 to 35 years). T h e initial white blood cell count (WBC) ranged from 3,6OO/pL to 800,OOO/pL (median, 164,00O/pL). I n 1 1 patients, W B C was greater than 50,00O/pL and in 8 patients, WBC was greater than lOO,OOO/ pL. T h e surface antigen profile of leukemic blasts was determined in all patients at the time of diagnosis and/or relapse before BMT. of 14 cases (100%) expressed CD7. The cytogenetic features of leukemic blasts were examined in eight patients. Of these eight patients, four (UPN 643, 836, 882, 1051) had a pseudodiploid karyotype with structural chromosomal abnormalities (data not shown). Four patients were in first remission, five were in second remission, and five were in third remission. Five patients had prior extramedullary relapses. Of these five patients, two had central nervous system (CNS) relapses, one had testicular relapse, one had testicular involvement and leukemia cutis at relapse, and one had tonsillary relapse. In the four patients who were in first remission, the time from diagnosis to BMT ranged from 3 to 5 months. Of these four patients, UPN 692 was an adult male whose initial WBC was 120,OOO/pL, UPN 701 was an adult male whose initial WBC was 74,8OO/pL, UPN 836 was an adolescent male with an initial WBC of 17,9OO/pL and a pseudodiploid karyotype, and UPN 1051 was an adult male. In the remaining 10 patients, who were in 2nd or 3rd remission, the duration of first remission ranged from 2 to 28 months (median, 10 months), and the time from diagnosis to BMT ranged from 13 months to 56 months (median, 20 months). Two of these 10 patients were in their first BM remission but had experienced an extramedullary relapse. In the remaining eight, who were in their second or third BM remission, the median duration of the first BM remission was 10.5 months (range, 2 to 53 months). Quantitative analysis of BM remission status by multiparameter fluorescence-activated flow cytometry, cell sorting, and leukemic progenitor cell assays. The remission status of the BM was confirmed in all patients within 10 days before the preparative regimen. As shown in Table 1 , the percentage of lymphoblasts in the pretransplant BM biopsy specimens ranged from 0% to 3.1% (median, 0.4%) and percentage of TdT' cells ranged from 0% to 6% (median, 0%). To further assess the BM remission status of patients, we performed a quantitative analysis of residual leukemia in the remission BM specimens by using an experimental detection assay system for occult leukemia, which combines multiparameter fluorescence activated flow cytometry, cell sorting, and in vitro LPC assays, as described in the Materials and Methods. Because leukemic blasts from some patients (UPN 643,665, 735, 882, 1081) at the time of diagnosis or relapse before BMT were CD3+, we analyzed both the immature CD3 (red)-as well as the mature CD3 (red)+ fractions of CD5/CD7 (green)+ T-lineage cells in the lymphoid light scattering window for the presence of T-lineage LPCs. The percentage of CD3-CD5,7+ immature T-lineage lymphoid cells showed a significant degree of interpatient variation ranging from 5.8% (UPN 767) to 19.9% (UPN 1051) (median, 13.3%) ( Table 2) . FACS sorted virtually pure populations of CD3-CD5,7+ cells from 11 of 13 patients formed 12 to 540 (median, 86) compact 20-to 50-cell colonies per 100,000 cells when cultured in the presence of rIL-2 and PHA-LCM in the LPC assay system (Table 2) . Colony cells had blast morphology with a basophilic cytoplasm, high nuclear to cytoplasmic ratio, highly irregular nuclear membrane, and prominent nucleoli (Fig 1 and 2 ).
Sufficient cells for immunophenotypic analyses were obtained in six cases. As will be detailed later in this section, colony blasts in these six cases were found to be strongly positive for nuclear TdT, surface CD2, CD5, and CD7, as well as for cytoplasmic CD3, but they were negative for surface CD3 or CD25, consistent with T-lineage ALL. The percentage of CD3+CD5,7+ T-lineage lymphoid cells among MNCs ranged from 2.8% (UPN 767) to 37.3% (UPN 882) (median, 13.2%). FACS sorted CD3+CD5,7+ cells from 12 of 13 patients formed 20-to 500-cell colonies in the LPC assay system. However, in 7 of these 12 cases (UPN 692, 701, 735, 767, 817, 836, 1051), colonies were loose rather than compact, had an irregular shape, and were formed by diffusely associated 200 to 500 small cells growing in "sheets." Isolated colony cells from these cultures displayed small mature normal lymphocyte morphology and had the composite immunophenotype normal healthy volunteer donors formed diffusely associated 200 to 500 cell colonies containing TdTCD2+CD3+CD5+CD7'CD25+ mature "activated" T lymphocytes. Since a blast colony was defined as >20 tightly associated TdT+ T-cell precursor cells and no TdT' cells were detected on cytospin preparations of pooled colonies, it was assumed that none of the observed colonies in these cases was composed of TdT' T-lineage ALL blasts.
Controls included EM specimens from two healthy volunteers, one high-risk T-lineage ALL patient in partial relapse, two newly diagnosed T-lineage ALL patients, and one high-risk remission E-lineage ALL patient.
Abbreviation: ND, not determined.
TdT-CD2+CD3(surface)+CD5+CD7 +CD25+. Hence, colonies in these seven cases most likely comprised IL-2 responsive normal mature T-cell populations. In the remaining five patients (UPN 643, 654, 665, 882, and 1081), whose fresh leukemic BM blasts a t diagnosis expressed the CD3 antigen on their surface, the vast majority of colonies from day 7 cultures of FACS sorted CD3+CD5,7+ lymphoid cells were spherical, compact, and were formed by 20 to 100 tightly associated round cells with a distinct cell border of high refractility. Isolated colony cells displayed blast morphology with a highly irregular nuclear membrane and prominent nucleoli, and, as detailed later in this section, they had the composite immunophenotype TdT+CD2+CD3+CDSCCD7+ CD25-,consistent with T-lineage ALL (Fig 2) . The number of CD5,7+ T-lineage LPC per lo8 MNCs in the remission BM, which was calculated from the percentages of CD3-CD5,7+ and CD3'CD5,7+ lymphoid cells and the sum of the number of blast colonies in these fractions, showed a marked interpatient variation, ranging from less than 233 to 214,047 (median, 8,568). These findings indicated that the remission BMs from our high-risk remission T-lineage ALL patients contained less than 0.0002% to 0.2% (median, 0.0086%) residual T-lineage LPC.
In parallel experiments shown in Table 2 , we analyzed "negative control BMs" from two healthy volunteer donors and one high risk remission B-lineage ALL patient. The percentages of CD3-CD5,7+ lymphoid cells in these control BMs ranged from 0.5% to 2%. FACS sorted CD3-CD5,7" lymphoid cells yielded 0 to 26 20-to 30-cell colonies per lo5 cells cultured, which were composed of small round TdTlymphoid cells with a regular nuclear membrane. These colony cells were not further characterized because of the limited cell numbers. By comparison, the percentages of CD3+CD5,7+ lymphoid cells ranged from 2.7% to 8.8%. FACS sorted CD3+CD5,7+ lymphoid cells yielded 10 to greater than 100 100-to 200-cell colonies, which were composed of diffusely associated small mature lymphocytes. The composite immunophenotype of isolated colony cells was TdT-CD3+CDS+CD7+CD25+, consistent with a normal "activated" T-cell marker profile (data not shown). Also For personal use only. on September 14, 2017. by guest www.bloodjournal.org From analyzed were "positive control BMs" from one T-lineage ALL patient in partial relapse containing 12% blasts and two newly diagnosed T-lineage ALL patients containing 96% to 98% blasts. The percentages of CD3-CD5,7+ lymphoid cells in these positive control BMs ranged from 18.6% to 86.2%. FACS sorted CD3-CD5,7+ lymphoid cells yielded 0 to 294 20-to 30-cell colonies per lo5 cells cultured, which were composed of TdT+CDS+CD7+CD25-blasts. By comparison, the percentages of CD3+CD5,7+ lymphoid cells ranged from 0.9% to 27.8%. FACS sorted CD3+CD5,7+ lymphoid cells yielded no blast colonies in one of these samples. In the remaining two cases, FACS sorted CD3+CD5,7+ lymphoid cells yielded 175 to 1,360 compact 20-to 50-cell colonies containing TdT'CD3 +CD5 +CD7+CD25-blasts.
Eflects of ex vivo marrow purging on residual leukemic blasts in autografts. As detailed in the Materials and Methods, autografts were purged ex vivo with a combination of TIOl/CDS-Ricin and G3.7/CD7-Ricin immunotoxins plus 4-HC. The rationale of combining immunotoxins with 4-HC has been published in previous report^.'^.'^ To accurately determine the destruction of residual T-lineage LPC in the autografts, we used multiparameter flow cytometry, cell sorting, and LPC assays, as described in the Materials and Methods. When CD3-CD5,7+ and CD3 +CD5,7+ T-lineage lymphoid cells from postpurge autograft samples were isolated by sterile multiparameter cell sorting and assayed for T-lineage ALL blast colony formation in the LPC assay system, no blast colonies were observed in the postpurge samples from 11 of 13 patients. In the remaining 2 patients (UPN 665 and 701), there were 7 (98% reduction in clonogenicity as compared with prepurge samples) and 124 (no reduction in clonogenicity as compared with prepurge samples) blast colonies per lo5 cells plated (Table 3) . The estimated numbers of T-lineage LPC in the postpurge autografts ranged from less than 14 LPC/108 MNC (ie, t0.000014% of MNC) in UPN 675 to 1,488 LPC/108 MNC (ie, 0.00148% of MNC) (Table 3) . Hence, 0.8 logs to greater than 3.4 logs (82.6% to >99.96%) of residual LPC were eliminated from autologous remission autografts by the applied combined immunochemopurging protocol. Since all analyzed cases were in complete remission, a more accurate measurement of the log kill efficacy of the purging procedure was hampered by the limit of sensitivity, which is determined by the numbers of residual LPC in prepurge autograft samples.
BMT, engraftment, and posttransplant complications. As detailed in the Materials and Methods section, the first nine patients were prepared for BMT with single dose TBI plus high dose Ara-C and the subsequent five patients were prepared with hyperfractionated TBI plus high dose cyclophosphamide. The posttransplant course of the patients is detailed in Table 4 . The median BM cell dose of the autografts was 0.54 x 10' MNC/kg (range, 0.23 to 0.78 x lo8 MNC/kg). By multiplying the number of LPC per 10' MNC and the cell dose (MNC per kilogram) of the reinfused autografts, we estimated the number of reinfused T-lineage LPC per kilogram. These values ranged from less than 8 LPC/kg in UPN 675,735, and 836 to 655 LPC/kg in UPN 701 (Table 4) . Thirteen of 14 patients engrafted, as defined by a WBC greater than l,OOO/pL for 3 consecutive days, at a median of 23 days (range, 18 to 62 days) post-BMT. The median time to reach an absolute neutrophil count (ANC) greater than 5OO/pL was 27 days (range, 16 to 63 days) (Table 4) . One patient (UPN 735) had an ANC >5OO/pL at day 28 but died at 38 days in respiratory failure secondary to aspergillus pneumonitis. Two patients (UPN 692 with initial engraftment at 62 days and UPN 701 with initial engraftment at 30 days) had poor hematologic recovery with persistent leukopenia, anemia, and thrombocytopenia. UPN 692 received an untreated "back-up" autograft containing 1.0 x lo8 nucleated cells/kg on day 98 post-BMT and UPN 701 received an untreated back-up autograft containing 0.2 x lo8 nucleated cells/kg on day 105 post-BMT. Despite the reinfusion of untreated back-up BM, these For patients continued to have poor BM function and died of hemorrhage at 139 days and 131 days post-BMT, respectively. Nine patients relapsed at 37 to 510 days (1.2 to 17 months, median, 65 days/2.2 months) post-BMT and 6 have subsequently died of leukemia (Table 4) . Two patients (UPN 81 7 and UPN 836) are alive and disease free at 28 and 26 months post-BMT.
Sequential analysis of the composite immunophenotypes of leukemic blasts obtained from T-lineage ALLpatients at diagnosis, relapse, or during remission before BMT, and at relapse after BMT. As illustrated in Table 5 , the composite immunophenotypes of TdT+ T-lineage ALL colony blasts in cultures of either CD3-CD5,7+ or CD3+CD5,7+ FACS sorted remission BM lymphoid cells showed striking similarities to those of fresh BM blasts at the time of diagnosis, relapse before BMT, and/or relapse after BMT. For example, in UPN 643, the composite immunophenotype of colony blasts in cultures of FACS sorted CD3+CD5,7' lymphoid cells was C D 1 -CD2'CD3 + CD5 +CD7 'CD 19-CD25-, which is similar to that of fresh BM blasts obtained at relapse before or after BMT. In view of the pronounced immunophenotypic heterogeneity of T-lineage ALLs,l2<l3 the observed similarities between the composite immunophenotypes of colony blasts in LPC assays and the composite immunophenotypes of freshly obtained primary BM provided suggestive evidence that the T-lineage LPC assays may detect those LPC clones that are biologically relevant in vivo. These intriguing findings prompted us to investigate the correlation between the numbers of LPC in remission BMs and the probability of remaining in remission post-BMT.
Correlation between probability of remaining in remission post-BMT and patients' pre-BMT characteristics. We examined the potential influence of the residual leukemia burden a t the time of BMT, as measured by our new MRD detection assay system and expressed as the number of LPC/ lo8 M N C in the remission BM samples before BMT, on the probability of remaining free of relapse and DFS, after BMT. To this end, we divided the patients into two groups composed of those with LPC numbers less than (group 1) versus those with LPC numbers equal or greater than (group 2) the calculated median of 8,568 LPC/lOs MNC. Figure 3 depicts the product-limit estimates for the probability of remaining in remission, and DFS, of these two groups. The Kaplan-Meier estimates and standard errors of the probability of remaining in remission after BMT were 14 13% for group 2 patients and 53 * 25% for group 1 patients, P = .006. An advantage in DFS was observed for group 1 (DFS: 0 +-0% for group 2 v 33 19% for group 1, P = .008). These correlations suggest a predictive value of the new MRD detection assay for the outcome of high risk remission T-lineage ALL patients undergoing autologous BMT. However, they are preliminary and have to be interpreted with caution because of the limited sample size. In contrast to the numbers of LPC, the percentage of TdT' cells, or percentage of lymphoblasts in remission BM immediately before BMT did not correlate with the probability of relapse after BMT.
Notably, eight of nine patients who relapsed post-BMT had no remaining LPC detected in their autografts after ex vivo purging (Table 3 ). In the remaining patient (UPN 665), 2.7 logs of contaminating LPC in the autograft were killed by the purging protocol and there were only 196 residual LPC/108 M N C (0.0002%) in the purged autograft. Hence, no apparent association existed between the outcome and the log kill efficacy of purging, the numbers of LPC/108 M N C in purged autografts, or the estimated numbers of LPC/kg reinfused to the patients.
DISCUSSION
The present report details the results obtained in 14 patients with high T-lineage ALL who underwent autologous BMT in complete remission for treatment of their residual disease. In agreement with previous report^,',^,^.'.^',^^ recurrence of leukemia was the leading cause of treatment failure and was experienced by 9 of 14 patients, indicating that the For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Immunologic marker profiles were determined as described in Materials and Methods.
Abbreviations: CB, colony blasts; (s), surface: (c), cytoplasmic; ND, not determined. *Blasts were judged to be positive for TdT but the percentage of positivity was not quantitatively determined.
residual leukemia in the majority of high-risk remission T-lineage ALL patients is resistant to radiochemotherapy. Until more effective preparative regimens become available, laboratory methods that more accurately assess and monitor the quality of remission would allow patients to be transplanted a t a time when their residual disease burden is minimal, and the probability of a given preparative regimen to eradicate residual disease is optimal. Therefore, considerable effort has been invested in developing highly sensitive MRD detection methods capable of detecting very small numbers of contaminating leukemic blasts in remission BM samples, which are not discernible by conventional morphologic examinations or imm~nophenotyping.~~.~'
In this study, we used a novel quantitative MRD detection assay system that combines fluorescence activated multiparameter flow cytometry and cell sorting with LPC assays to analyze remission BM samples from T-lineage ALL patients for the presence of residual clonogenic leukemic blasts. Notably, high numbers of residual LPCs detected in remission BM before BMT appeared to indicate a poor prognosis, providing evidence for the biologic significance and clinical value of in vitro T-lineage ALL LPC assays and suggesting that the in vitro clonogenic blasts detected by LPC assays likely represent the in vitro counterparts of the in vivo clonogenic T-lineage ALL blasts. Two possible explanations for the observed association between LPC numbers in remission marrow and outcome after autologous BMT are (1) LPC numbers may accurately reflect the total leukemia burden or its clonogenic pool, which determines outcome, or (2) the assay system favors the outgrowth of drug/radiation resistant leukemic clones, and the number of such clones will likely affect outcome. Whether the MRD data generated in this new assay system will add useful information and predictive strength to established prognostic parameters, such as WBC at diagnosis and remission number, will be the subject of a separate long-term study on a larger patient population.
Unlike cytogenetic or molecular biologic analyses of the remission BM samples for the presence of clonal populations of leukemic blast^,*'^^^ our assay system for minimal residual leukemia does not depend on the presence of clonal chromosomal abnormalities or the availability of clonospecific probes. The opportunity is thus provided to routinely use this more generally applicable assay system to predict the outcome of high risk remission T-lineage ALL patients. In addition, a quantitative analysis of remission BMs for the presence of clonogenic ALL blasts using multiparameter flow cytometry and LPC assays will probably yield biologically more relevant information about the quality of remission than a qualitative analysis for the presence of ALL blasts, using methods that do not discriminate between leukemic cells of different proliferative capacities, such as the amplification of DNA sequences flanking the crossover sites of certain clonotypic chromosomal translocations, or amplification of rearranged T-cell receptor gamma or delta chain sequences using the PCR t e c h n i q~e .~~-~'
A potential limitation of autologous BMT is the likely presence of residual leukemic blasts in the remission autografts, which could contribute to leukemic relapse. Therefore, most centers have used autografts that were harvested in complete remission when the residual leukemia burden in the BM is believed to be minimal, and which were purged ex vivo using immunologic or pharmacologic methods in an attempt to eradicate occult leukemic cells. In the present study, autografts were purged ex vivo using the [TlOl/anti-CDS-Ricin + G3.7/anti-CD7-Ricin + 4-HCI combined immunochemotherapy protocol. This purging protocol was previously found to be highly effective against clonogenic blasts of several in vitro established T-lineage ALL cell lines, as well as against fresh LPCs from T-lineage ALL patients.l3.I4 Furthermore, the antileukemic efficacy of this combined protocol was found to be superior to the antileukemic efficacy of alternative purging protocols which used immunotoxins alone or 4-HC Thirteen of 14 patients engrafted at a median of 23 days verifying the repopulation capacity of autografts treated by this new purging protocol. Consistent with our previous report^,'^ the [TIOI-Ricin + G3.7-Ricin + 4-HCI combined immunochemotherapy protocol was very effective against residual T-lineage LPC in the remission autografts and killed 98% to 100% (maximum kill, 23.4 logs, >99.96%) of contaminating LPC in 10 of 11 evaluable patients. However, despite effective ex vivo purging of autografts, nine patients relapsed at a median of 2.2 months post-BMT. There was no apparent association between the outcome and the log kill efficacy of purging, the numbers of residual LPC in purged autografts, or the estimated numbers of LPC reinfused to the patients. These findings suggest that in our series of high-risk remission T-lineage ALL patients, the primary reason for the recurrence of leukemia after autologous BMT was not the reinfusion of leukemic blasts in autografts due to inefficient ex vivo purging, but rather the inability of the preparative regimens to eradicate the therapy refractory residual in vivo leukemia burden of the patients.
The predictive value of the described MRD assay system for the outcome of high-risk remission T-lineage ALL patients undergoing autologous BMT supports our hypothesis that the in vitro clonogenic T-lineage ALL blasts represent the in vitro counterparts of the in vivo clonogenic T-lineage ALL LPCs. Until more effective preparative regimens are developed to successfully eliminate the residual leukemia burden in high-risk remission ALL patients, recurrence of disease will most likely continue to be the leading cause of failure and death after BMT. An accurate assessment of the quality of BM remission before BMT using this novel MRD detection assay might allow us to determine the optimal timing for BMT and the need for additional therapy to achieve a more substantial remission with less residual leukemia burden.
